Forecast Period 
Market Size (Base Year) 
Market Size (Forecast Year)
CAGRGlobal Age-Related Macular Degeneration (AMD) Disease Market, By Type (Dry AMD and Wet AMD), End User (Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Home Healthcare and Others), Distribution Channel (Direct Tender and Retail Sales) – Industry Trends and Forecast to 2030.
Age-Related Macular Degeneration (AMD) Disease Market Analysis and Size
The market is predicted to be driven primarily by the introduction of innovative treatments for age-related macular degeneration (AMD), an increase in AMD prevalence and a robust product pipeline. Around 196 million persons worldwide were estimated to have age-related macular degeneration in 2020, including around 10.4 million cases of moderate-to-severe vision impairment. According to figures from the UN Department of Economic and Social Affairs, there will be about 727 million people who are 65 years of age or older in the world in 2020. Thus, this factor will boost the growth of market.
Data Bridge Market Research analyses that the age-related macular degeneration (AMD) disease market which is USD 1.81 billion in 2022, is expected to reach USD 3.08 billion by 2030, at a CAGR of 6.9% during the forecast period 2023 to 2030. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Age-Related Macular Degeneration (AMD) Disease Market Scope and Segmentation
|
Report Metric |
Details |
|
Forecast Period |
2023 to 2030 |
|
Base Year |
2022 |
|
Historic Years |
2021 (Customizable to 2015 - 2020) |
|
Quantitative Units |
Revenue in USD Billion, Volumes in Units, Pricing in USD |
|
Segments Covered |
Type (Dry AMD and Wet AMD), End User (Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Home Healthcare and Others), Distribution Channel (Direct Tender and Retail Sales) |
|
Countries Covered |
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America |
|
Market Players Covered |
Loop Road Holdings LLC (U.S.), Old Saw Mill Holdings LLC (U.S.), OSMR LLC (U.S.), Regeneron Capital International B.V. (Netherlands), Regeneron International Limited (Ireland), F. Hoffmann-La Roche Ltd (Switzerland), Novartis AG (Switzerland), Bayer AG (Germany), Abbvie, Inc (U.S.) |
|
Market Opportunities |
|
Market Definition
The eye condition known as age-related macular degeneration (AMD) can harm the macula, which is responsible for clear, straight-ahead vision. This causes centre vision to become fuzzy. An aberrant increase in blood vessel growth may result in vision loss. Occasionally, aberrant new blood vessels might be seen growing from the choroid into the macula. Between the retina and the outer, solid coat of the eye lies a layer of blood vessels called the choroid (sclera). The retina's ability to function may be hampered by these aberrant blood vessels that may leak fluid or blood. In older persons, macular degeneration is frequent.
Age-Related Macular Degeneration (AMD) Disease Market Dynamics
Drivers
- Growing Adoption of Treatment Drugs
Wet macular degeneration can be treated with a variety of medications, which contributes to the market's expansion. As an illustration, the FDA approved Eylea, an intravitreal injection of aflibercept, in 2011. In wet AMD, it prevents VEGF from operating. It effectively treats patients with macular edoema, wet AMD, and diabetic macular edoema. In addition, individuals who received Beovu experienced intraocular inflammation that was four times larger than what patients who received Eylea experienced. People are influenced by such factors to select Eylea over Beovu. As a result, this component spurs market expansion.
- Increased Growth of Hospital Pharmacy
The Royal National Institute of Blind People (RNIB) estimates that in 2021, 26.5 million people will be at a high risk of developing this ailment. The majority of patients are effectively treated with medications like Lucentis, Eylea, and Beovu, which are given intravenously in hospitals, under the supervision of experts. As a result, it is anticipated that the rising demand for wet AMD therapy will increase hospital visits, driving up the market in this area.
Opportunities
- Rising Healthcare Expenditure and Government Support
The increasing incidence of cancer and the growing knowledge of the condition and its treatments are both improving. The market is anticipated to grow faster as a result of several government programmes that tend to offer better and more practical therapies along with favourable reimbursement regulations. Additionally, the market is anticipated to be driven by the rising acceptability of sophisticated therapies.
Restraints/Challenges
- Side-Effects of Wet AMD Drugs
There are various wet AMD medications that have a variety of side effects, which restrains the market's expansion. Effects including retinal vasculitis, intraocular inflammation, concurrent vascular occlusion, nausea, vomiting, and permanent vision loss in individuals are anticipated to restrain growth. This inhibits market expansion.
This age-related macular degeneration (AMD) disease market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the age-related macular degeneration (AMD) disease market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
COVID-19 Impact on the Age-Related Macular Degeneration (AMD) Disease Market
The market for age-related macular degeneration suffered during the early stages of the COVID-19 pandemic as a result of missing or delayed follow-up for AMD treatment, which led to non-adherence to medication. For instance, Roche said in July 2020 that sales of its AMD medication Lucentis rose only modestly to USD 401 million in the second quarter from the same time the year before. Only a small number of medications, mostly anti-VEGFs are now authorized for the treatment of age-related macular degeneration. Anti-VEGF medications necessitate frequent and uncomfortable intraocular injections, which adds to the strain and causes non-adherence to therapy. Companies are working on longer-acting anti-VEGFs and vitreous implants that enable sustained medication delivery to circumvent this obstacle. Over the next years, it is projected that the release of long-acting anti-VEGF drugs such as Beovu and Vabysmo will fuel market expansion.
Recent Developments
- In 2021, For the treatment of wet AMD, myopic choroidal neovascularization and retinal vein occlusion, Biogen Inc. and Samsung Bioepis Co., Ltd. received U.S. FDA approval for their biosimilar version of Lucentis under the brand name BYOOVIZ.
- In 2021, A research partnership for the creation of a medication to treat people with dry age-related macular degeneration was established by Mosaic Biosciences and Ocular Therapeutix. This partnership improves the company's R&D portfolio and presents a significant possibility for the business to grow.
Global Age-Related Macular Degeneration (AMD) Disease Market Scope
The age-related macular degeneration (AMD) disease market is segmented on the basis of type, end-user and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Type
- Dry AMD
- Wet AMD
End User
- Hospitals
- Specialty Clinics
- Ambulatory Surgical Centers
- Home Healthcare
- Others
Distribution Channel
- Direct Tender
- Retail Sales
Age-Related Macular Degeneration (AMD) Disease Market Regional Analysis/Insights
The age-related macular degeneration (AMD) disease market is analyzed and market size insights and trends are provided by country, type, end-user and distribution channel as referenced above.
The countries covered in the age-related macular degeneration (AMD) disease market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America dominates the age-related macular degeneration (AMD) disease market because of the presence of well-developed healthcare infrastructure and favourable reimbursement policies in the region.
Asia-Pacific is expected to grow at the highest growth rate in the forecast period of 2023 to 2030 due to the rapid growth in the number of hospitals and diagnostic labs as well as the expansion of access to health care in densely populated nations like China, India, and South Korea.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Age-Related Macular Degeneration (AMD) Disease Market Share Analysis
The age-related macular degeneration (AMD) disease market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to age-related macular degeneration (AMD) disease market.
Some of the major players operating in the age-related macular degeneration (AMD) disease market are:
- Loop Road Holdings LLC (U.S.)
- Old Saw Mill Holdings LLC (U.S.)
- OSMR LLC (U.S.)
- Regeneron Capital International B.V. (Netherlands)
- Regeneron International Limited (Ireland)
- F. Hoffmann-La Roche Ltd (Switzerland)
- Novartis AG (Switzerland)
- Bayer AG (Germany)
- Abbvie, Inc (U.S.)
SKU-
